Transplant rejection clues sought in patient proteins
NCT ID NCT01163578
First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This study is looking at proteins in the blood and tissues of people who have received an organ or bone marrow transplant. The goal is to learn more about how anti-rejection drugs work and why some people reject their transplant while others do not. Researchers will follow 1,200 patients of all ages at the University of Pittsburgh Medical Center.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better ways to monitor and treat organ rejection after transplant.
- What could go wrong
- This is an observational study, not testing a new treatment. It may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,200 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Mar 2005
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals who are listed and or recipients of solid organ or bone marrow transplantation.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Recipients of abdominal, thoracic and bone marrow allografts that are receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center. * All Ages * Subject or parents are able to read and understand the informed consent Exclusion Criteria: * Subjects and/or their parents who are unable to read and understand informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone marrow transplantation are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Children's Hospital of Pittsburgh of UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can we outsmart Drug-Resistant CMV in transplant patients?
- DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
- Artificial intelligence could help prevent transplant complications by personalizing drug dosing
- New study to test antifungal drug safety in organ transplant patients
- Can a dialysis-like treatment save kids with lung failure after transplant?
- Can a wearable glucose sensor be trusted in the ICU? new study aims to find out